Edition:
United Kingdom

Coherus BioSciences Inc (CHRS.OQ)

CHRS.OQ on NASDAQ Stock Exchange Global Market

20.07USD
20 Aug 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$20.07
Open
$19.72
Day's High
$20.14
Day's Low
$19.59
Volume
176,826
Avg. Vol
305,463
52-wk High
$23.43
52-wk Low
$8.34

Latest Key Developments (Source: Significant Developments)

Amgen loses appeal against Coherus BioSciences over patent for purifying proteins
Monday, 29 Jul 2019 

July 29 (Reuters) - u.s. Appeals court upholds dismissal of amgen patent infringement lawsuit against coherus biosciences -- court ruling:.  Full Article

Coherus Biosciences Q1 Loss Per Share $0.29
Thursday, 9 May 2019 

May 9 (Reuters) - Coherus BioSciences Inc ::COHERUS BIOSCIENCES REPORTS CORPORATE HIGHLIGHTS AND FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.29.Q1 EARNINGS PER SHARE ESTIMATE $-0.46 -- REFINITIV IBES DATA.CASH AND CASH EQUIVALENTS AND INVESTMENTS IN MARKETABLE SECURITIES FOR Q1 TOTALED $96.4 MILLION AS OF MARCH 31, 2019.  Full Article

Coherus Biosciences And Amgen Settle Trade Secrets Action
Thursday, 2 May 2019 

May 2 (Reuters) - Coherus BioSciences Inc ::COHERUS BIOSCIENCES AND AMGEN SETTLE TRADE SECRETS ACTION.COHERUS BIOSCIENCES - DETAILS OF SETTLEMENT ARE CONFIDENTIAL, COHERUS TO CONTINUE TO MARKET UDENYCA & PAY MID-SINGLE DIGIT ROYALTY TO AMGEN FOR 5 YEARS.COHERUS BIOSCIENCES - SETTLED TRADE SECRET ACTION BROUGHT BY AMGEN AGAINST COHERUS THAT WAS PENDING IN SUPERIOR COURT OF CALIFORNIA COUNTY OF VENTURA.  Full Article

Coherus Biosciences Reports Fourth Quarter And Full Year 2018 Financial Results
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Coherus BioSciences Inc ::COHERUS BIOSCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.92.Q4 EARNINGS PER SHARE ESTIMATE $-0.86 -- REFINITIV IBES DATA.  Full Article

Coherus BioSciences Announces Global Settlement With AbbVie Securing Rights To Commercialize Its Adalimumab Biosimilar Candidate, CHS-1420
Friday, 25 Jan 2019 

Jan 25 (Reuters) - Coherus BioSciences Inc ::COHERUS BIOSCIENCES ANNOUNCES GLOBAL SETTLEMENT WITH ABBVIE SECURING RIGHTS TO COMMERCIALIZE ITS ADALIMUMAB BIOSIMILAR CANDIDATE, CHS-1420.COHERUS BIOSCIENCES INC - FINANCIAL TERMS ARE NOT DISCLOSED..COHERUS BIOSCIENCES INC - FINANCIAL TERMS ARE NOT DISCLOSED.COHERUS BIOSCIENCES - GLOBAL SETTLEMENTS RESOLVE ALL PENDING DISPUTES BETWEEN PARTIES RELATED TO COHERUS' ADALIMUMAB BIOSIMILAR.COHERUS BIOSCIENCES INC - UNDER U.S. SETTLEMENT, COHERUS' LICENSE PERIOD IN U.S. COMMENCES ON DECEMBER 15, 2023.COHERUS BIOSCIENCES INC - CURRENTLY PREPARING BIOLOGICS LICENSE APPLICATION FOR CHS-1420 FOR SUBMISSION TO FDA WITH ANTICIPATED FILING IN LATE 2019.COHERUS BIOSCIENCES INC - COHERUS WILL PAY ROYALTIES TO ABBVIE.COHERUS BIOSCIENCES INC - CONTINUES TO EVALUATE OPTIONS AND POTENTIAL STRATEGIES FOR EX-U.S. COMMERCIALIZATION OF CHS-1420.  Full Article

Coherus BioSciences Announces Prime Vendor Program Contract Agreement With Apexus
Friday, 30 Nov 2018 

Nov 30 (Reuters) - Coherus BioSciences Inc ::COHERUS BIOSCIENCES ANNOUNCES APEXUS CONTRACT AGREEMENT FOR 340B HOSPITALS AND CLINICS, AND Q-CODE ISSUANCE FROM CMS.COHERUS BIOSCIENCES INC - HAS RECEIVED Q-CODE MEDICAL BILLING STATUS FOR UDENYCA FROM CENTERS FOR MEDICARE AND MEDICAID SERVICES.  Full Article

Coherus Biosciences Q3 Loss Per Share $0.87
Thursday, 8 Nov 2018 

Coherus BioSciences Inc ::COHERUS BIOSCIENCES REPORTS CORPORATE HIGHLIGHTS AND THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.87.Q3 EARNINGS PER SHARE VIEW $-0.77 -- THOMSON REUTERS I/B/E/S.CASH AND CASH EQUIVALENTS AND INVESTMENTS IN MARKETABLE SECURITIES TOTALED $117.2 MILLION AS OF SEPTEMBER 30, 2018.  Full Article

Coherus BioSciences Says FDA Approves UDENYCA (pegfilgrastim-cbqv)
Friday, 2 Nov 2018 

Nov 2 (Reuters) - Coherus BioSciences Inc ::U.S. FDA APPROVES UDENYCA™ (PEGFILGRASTIM-CBQV).COHERUS BIOSCIENCES INC - UDENYCA™ (PEGFILGRASTIM-CBQV) APPROVED BY BOTH FDA & EUROPEAN COMMISSION.  Full Article

Coherus Biosciences Says ‍Had Cash And Cash Equivalents Of About $126.9 Million
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Coherus Biosciences Inc ::COHERUS BIOSCIENCES SAYS ‍HAD CASH AND CASH EQUIVALENTS OF ABOUT $126.9 MILLION AS OF DEC 31 - SEC FILING​.  Full Article

Coherus Says Judge Issued Under Seal Report & Recommendation In Relation To Patent Infringement Complaint
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Coherus Biosciences :COHERUS SAYS U.S. JUDGE RECOMMENDED COURT GRANT CO'S PENDING MOTION TO DISMISS AMGEN'S COMPLAINT FOR FAILURE TO STATE CLAIM .COHERUS BIOSCIENCES SAYS ON DEC 7, JUDGE ISSUED UNDER SEAL REPORT AND RECOMMENDATION TO DISTRICT COURT IN RELATION TO PATENT INFRINGEMENT COMPLAINT.COHERUS BIOSCIENCES SAYS CO EXPECTS DISTRICT COURT TO DECIDE IN Q1 2018 WHETHER TO ADOPT MAGISTRATE JUDGE'S RECOMMENDATION - SEC FILING.COHERUS BIOSCIENCES SAYS ‍REPORT AND RECOMMENDATION ISSUED BY JUDGE WITH RESPECT TO LITIGATION BETWEEN AMGEN, AMGEN MANUFACTURING LTD, CO​.  Full Article